BFV activates the NF-ΚB pathway through its transactivator (BTas) to enhance viral transcription

Virology

Volumn 400, Issue 2, 2010, Pages 215-223

  Wang, Jian ^a   Tan, Juan ^a   Zhang, Xihui ^a   Guo, Hongyan ^a   Zhang, Qicheng ^a   Guo, Tingting ^a   Geng, Yunqi ^a   Qiao, Wentao ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

Bovine foamy virus; BTas; NF B pathway; Viral transcription

Indexed keywords

I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P100; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SPUMA VIRUS; VIRUS TRANSCRIPTION;

ANIMALS; CATTLE; CELL LINE; CRICETINAE; HOST-PATHOGEN INTERACTIONS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; IMMUNOPRECIPITATION; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN INTERACTION MAPPING; SPUMAVIRUS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; VIRAL PROTEINS;

BOVINE FOAMY VIRUS;

EID: 77949567901     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.035     Document Type: Article

References (42)

1. Baldwin A.S. Series introduction: the transcription factor NF-kappaB and human disease. J. Clin. Invest. 2001, 107(1):3-6.
2. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25(6):280-288.
3. Briand G., Barbeau B., Tremblay M. Binding of HIV-1 to its receptor induces tyrosine phosphorylation of several CD4-associated proteins, including the phosphatidylinositol 3-kinase. Virology 1997, 228(2):171-179.
4. Broussard S.R., Comuzzie A.G., Leighton K.L., Leland M.M., Whitehead E.M., Allan J.S. Characterization of new simian foamy viruses from African nonhuman primates. Virology 1997, 237(2):349-359.
5. Conant K., Ma M., Nath A., Major E.O. Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-kappa B binding and protein kinase C activity in primary human astrocytes. J. Virol. 1996, 70(3):1384-1389.
6. Dejardin E., Droin N.M., Delhase M., Haas E., Cao Y., Makris C., Li Z.W., Karin M., Ware C.F., Green D.R. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002, 17(4):525-535.
7. Delelis O., Lehmann-Che J., Saib A. Foamy viruses-a world apart. Curr. Opin. Microbiol. 2004, 7(4):400-406.
8. Demarchi F., Gutierrez M.I., Giacca M. Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR. J. Virol. 1999, 73(8):7080-7086.
9. Diao L., Zhang B., Fan J., Gao X., Sun S., Yang K., Xin D., Jin N., Geng Y., Wang C. Herpes virus proteins ICP0 and BICP0 can activate NF-kappaB by catalyzing IkappaBalpha ubiquitination. Cell. Signal. 2005, 17(2):217-229.
10. Diao L., Zhang B., Xuan C., Sun S., Yang K., Tang Y., Qiao W., Chen Q., Geng Y., Wang C. Activation of c-Jun N-terminal kinase (JNK) pathway by HSV-1 immediate early protein ICP0. Exp. Cell Res. 2005, 308(1):196-210.
11. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109:S81-S96. Suppl.
12. Habraken Y., Piette J. NF-kappaB activation by double-strand breaks. Biochem. Pharmacol. 2006, 72(9):1132-1141.
13. Harhaj E., Blaney J., Millhouse S., Sun S.C. Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR. Virology 1996, 216(1):284-287.
14. Hatada E.N., Krappmann D., Scheidereit C. NF-kappaB and the innate immune response. Curr. Opin. Immunol. 2000, 12(1):52-58.
15. Hatama S., Otake K., Omoto S., Murase Y., Ikemoto A., Mochizuki M., Takahashi E., Okuyama H., Fujii Y. Isolation and sequencing of infectious clones of feline foamy virus and a human/feline foamy virus Env chimera. J. Gen. Virol. 2001, 82(Pt 12):2999-3004.
16. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18(18):2195-2224.
17. Herchenroder O., Renne R., Loncar D., Cobb E.K., Murthy K.K., Schneider J., Mergia A., Luciw P.A. Isolation, cloning, and sequencing of simian foamy viruses from chimpanzees (SFVcpz): high homology to human foamy virus (HFV). Virology 1994, 201(2):187-199.
18. Hill C.L., Bieniasz P.D., McClure M.O. Properties of human foamy virus relevant to its development as a vector for gene therapy. J. Gen. Virol. 1999, 80(Pt 8):2003-2009.
19. Hiscott J., Kwon H., Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J. Clin. Invest. 2001, 107(2):143-151.
20. Ishii T., Kwon H., Hiscott J., Mosialos G., Koromilas A.E. Activation of the I kappa B alpha kinase (IKK) complex by double-stranded RNA-binding defective and catalytic inactive mutants of the interferon-inducible protein kinase PKR. Oncogene 2001, 20(15):1900-1912.
21. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
22. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3(3):221-227.
23. Kucharczak J., Simmons M.J., Fan Y., Gelinas C. To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 2003, 22(56):8961-8982.
24. Lecellier C.H., Neves M., Giron M.L., Tobaly-Tapiero J., Saib A. Further characterization of equine foamy virus reveals unusual features among the foamy viruses. J. Virol. 2002, 76(14):7220-7227.
25. Linial M. Why aren't foamy viruses pathogenic?. Trends Microbiol. 2000, 8(6):284-289.
26. Liu J., Geng Y. Targets for the transacitivator in the long terminal repeat of bovine foamy virus. Acta Sci. Nat. Univ. Nankaiensis 1999, 32(2):87-92.
27. Materniak M., Bicka L., Kuzmak J. Isolation and partial characterization of bovine foamy virus from Polish cattle. Pol. J. Vet. Sci. 2006, 9(4):207-211.
28. Mogensen T.H., Paludan S.R. Molecular pathways in virus-induced cytokine production. Microbiol. Mol. Biol. Rev. 2001, 65(1):131-150.
29. Murray S.M., Linial M.L. Foamy virus infection in primates. J. Med. Primatol. 2006, 35(4-5):225-235.
30. Nabel G., Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987, 326(6114):711-713.
31. Rong B.L., Libermann T.A., Kogawa K., Ghosh S., Cao L.X., Pavan-Langston D., Dunkel E.C. HSV-1-inducible proteins bind to NF-kappa B-like sites in the HSV-1 genome. Virology 1992, 189(2):750-756.
32. Santoro M.G., Rossi A., Amici C. NF-kappaB and virus infection: who controls whom. EMBO J. 2003, 22(11):2552-2560.
33. Senftleben U., Cao Y., Xiao G., Greten F.R., Krahn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293(5534):1495-1499.
34. Surabhi R.M., Gaynor R.B. RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. 2002, 76(24):12963-12973.
35. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107(1):7-11.
36. Tan J., Qiao W., Wang J., Xu F., Li Y., Zhou J., Chen Q., Geng Y. IFP35 is involved in the antiviral function of interferon by association with the viral tas transactivator of bovine foamy virus. J. Virol. 2008, 82(9):4275-4283.
37. Tobaly-Tapiero J., Bittoun P., Neves M., Guillemin M.C., Lecellier C.H., Puvion-Dutilleul F., Gicquel B., Zientara S., Giron M.L., de The H., Saib A. Isolation and characterization of an equine foamy virus. J. Virol. 2000, 74(9):4064-4073.
38. Veiby, O.P., and Read, M.A., 2004. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Commentary re J. Guo et al., Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the NF-kappaB p65 subunit. Clin Cancer Res 2004;10:3333-3341. Clin. Cancer Res. 10(10), 3262-3264.
39. Williams B.R. Signal integration via PKR. Sci. STKE 2001, 89:RE2.
40. Williams S.A., Kwon H., Chen L.F., Greene W.C. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J. Virol. 2007, 81(11):6043-6056.
41. Xiao G., Harhaj E.W., Sun S.C. Domain-specific interaction with the I kappa B kinase (IKK)regulatory subunit IKK gamma is an essential step in tax-mediated activation of IKK. J. Biol. Chem. 2000, 275(44):34060-34067.
42. Xiao G., Cvijic M.E., Fong A., Harhaj E.W., Uhlik M.T., Waterfield M., Sun S.C. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 2001, 20(23):6805-6815.